19,925 Shares of Novo Nordisk A/S $NVO Acquired by Carret Asset Management LLC

Carret Asset Management LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 19,925 shares of the company’s stock, valued at approximately $755,000.

Several other large investors have also added to or reduced their stakes in the business. CoreCap Advisors LLC increased its holdings in Novo Nordisk A/S by 4.7% during the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after purchasing an additional 242 shares in the last quarter. Claro Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 1.2% during the third quarter. Claro Advisors Inc. now owns 21,868 shares of the company’s stock valued at $829,000 after buying an additional 256 shares during the last quarter. Carson Advisory Inc. boosted its position in shares of Novo Nordisk A/S by 2.2% during the first quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after buying an additional 268 shares during the last quarter. Byrne Asset Management LLC grew its holdings in Novo Nordisk A/S by 9.7% during the third quarter. Byrne Asset Management LLC now owns 3,055 shares of the company’s stock worth $114,000 after buying an additional 270 shares in the last quarter. Finally, Bradley Foster & Sargent Inc. CT grew its holdings in Novo Nordisk A/S by 0.6% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock worth $1,726,000 after buying an additional 272 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on NVO shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s third-quarter results and raised guidance have helped support investor interest. The Wegovy pill is reportedly seeing strong sales, with more than 5 million prescriptions, suggesting it may expand the market rather than simply replace injections. Novo Up 4% in a Month: How Should Investors Approach the Stock Now? Wegovy pill prescriptions
• Positive Sentiment: Reports of liver improvements in some Wegovy patients point to potential additional clinical benefits and patient demand beyond weight loss. Novo Nordisk reports liver improvements with Wegovy in some patients
• Neutral Sentiment: Novo’s ongoing share-repurchase program, part of a plan of up to DKK 15 billion over 12 months, may provide some support for shareholders but is not a new growth catalyst. Novo Nordisk share repurchase programme
• Neutral Sentiment: Some crypto-market commentary says Binance futures accounts are leaning long on NVO, a speculative positioning signal rather than evidence of a change in the company’s fundamentals. Binance Futures Accounts Lean Long on Novo Nordisk
• Negative Sentiment: The FDA is requiring GLP-1 drugs, including Novo’s treatments, to carry warnings about a rare eye condition that can cause permanent vision loss. The label change may increase safety concerns among patients and prescribers. US FDA orders new eye risk warnings for Ozempic, Zepbound
• Negative Sentiment: Competition from Eli Lilly and pricing pressure continue to cloud Novo’s longer-term growth outlook. Commentary also highlights weaker earnings and a loss of market leadership in injectable GLP-1 drugs, tempering enthusiasm about pill growth. Competition and pricing pressures Novo Nordisk’s 2026 transition year

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $41.40 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $184.85 billion, a price-to-earnings ratio of 10.43, a PEG ratio of 1.42 and a beta of 0.70. The stock has a 50 day moving average of $40.50 and a 200 day moving average of $43.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus.

The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world.

Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.